Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2023; 29(5): 825-833
Published online Feb 7, 2023. doi: 10.3748/wjg.v29.i5.825
Bone loss in chronic liver diseases: Could healthy liver be a requirement for good bone health?
Jelena Jadzic, Danijela Djonic
Jelena Jadzic, Danijela Djonic, Center of Bone Biology, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia
Author contributions: Jadzic J and Djonic D contributed to conceptualization; Jadzic J contributed to data acquisition, writing the original draft, and data visualization; Djonic D contributed to reviewing and editing and supervision; All authors approved the submitted version of the manuscript.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Danijela Djonic, MD, PhD, Professor, Center of Bone Biology, Faculty of Medicine, University of Belgrade, Dr. Subotica 4/2, Belgrade 11000, Serbia. ddjonic@yahoo.com
Received: September 27, 2022
Peer-review started: September 27, 2022
First decision: October 20, 2022
Revised: October 29, 2022
Accepted: January 11, 2023
Article in press: January 11, 2023
Published online: February 7, 2023
Core Tip

Core Tip: Secondary osteoporosis and increased bone fragility are frequently overlooked complications in patients with chronic liver disease (CLD). Recent publications agree that CLD-induced bone fragility depends on the etiology, duration, and stage of liver disease, but certain ambiguities are still present. Importantly, etiopathogenetic mechanisms leading to CLD-induced bone loss are still insufficiently clarified. Given that available clinical tools for fracture risk assessment are not entirely reliable, evaluating small-length structural bone properties could improve understanding of the multifactorial nature of bone fragility in CLD patients, which could set a base for the development of more effective preventive and therapeutic strategies.